Over the past six months, Sarepta Therapeutics' stock has been influenced by several events: the Q3 2026 earnings report in early November 2026 showed the company beating analyst estimates for both EPS ($0.13 vs. $0.07 consensus) and revenue ($381.35 million vs. $352.20 million expected), despite a 13% year-over-year decrease in total product revenues driven by lower ELEVIDYS sales. The company raised the lower end of its full-year 2026 total net product revenue guidance to $1.25 billion–$1.3 billion, attributing it to strong PMO franchise performance and stable ELEVIDYS demand, though shares fell 7.5% post-report. While ELEVIDYS sales declined in Q3 2026, demand indicators were stable, with Q4 revenue expected to be in line with Q3, and the company plans to seek FDA approval for ELEVIDYS use in children under age 4 around mid-2027. The exon-skipping (PMO) franchise demonstrated continued strength, achieving $240 million in net revenue in Q3 and increased new patient enrollments. Positive pipeline advancements for key gene therapy programs, including promising data for DM1 and FSHD readouts, contributed to investor optimism, with the company moving quickly into registrational studies for these indications. Sarepta faces significant regulatory and safety hurdles for its key therapies, including patient deaths and black box warning requests for ELEVIDYS, and decided not to resume enrollment in the ENVISION study for non-ambulatory patients due to operational and technical barriers, delaying potential label expansion. The company recorded $52 million in take-or-pay charges related to non-cancelable manufacturing obligations for ELEVIDYS inventory, which impacted gross margins. Analyst ratings and price targets were updated by several research firms, with some downgrades (Needham & Company LLC, Wall Street Zen, Piper Sandler) and some upgrades or raised targets (William Blair, RBC Capital).